Mangoceuticals (NASDAQ:MGRX) Stock Rating Upgraded by Wall Street Zen

Mangoceuticals (NASDAQ:MGRX) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mangoceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Mangoceuticals Price Performance

MGRX opened at $0.52 on Friday. The business has a fifty day moving average price of $0.40 and a 200 day moving average price of $0.43. Mangoceuticals has a 12 month low of $0.16 and a 12 month high of $2.75. The stock has a market capitalization of $8.94 million, a price-to-earnings ratio of -0.35 and a beta of 2.28.

Mangoceuticals (NASDAQ:MGRX) last announced its quarterly earnings data on Tuesday, May 19th. The company reported ($0.22) earnings per share (EPS) for the quarter. The company had revenue of $0.07 million during the quarter. Mangoceuticals had a negative net margin of 4,639.13% and a negative return on equity of 112.00%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after purchasing an additional 6,928 shares during the last quarter. Virtu Financial LLC purchased a new position in Mangoceuticals during the 4th quarter worth $25,000. Boothbay Fund Management LLC acquired a new position in Mangoceuticals in the fourth quarter valued at $28,000. Jane Street Group LLC purchased a new stake in shares of Mangoceuticals in the fourth quarter valued at about $35,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Mangoceuticals during the fourth quarter worth about $102,000. 56.72% of the stock is owned by hedge funds and other institutional investors.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.